MOLECULAR MODELLING DESIGN AND OPIOID BINDING AFFINITY EVALUATION OF NEW 4-CHROMANONE DERIVATIVES

Mohammed Oday Ezzaat\(^1\) and Basma M. Abd Razik\(^2\)

Address(es):
\(^1\)Department of Chemistry, College of Education for Women, University of Anbar, 31001, Ramadi, Anbar, Iraq. \(^2\)Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriya University, 10001, Baghdad, Iraq.

*Corresponding author: edw.mohamed_oday@uoanbar.edu.iq

ARTICLE INFO

Received 24. 6. 2020
Revised 23. 9. 2020
Accepted 24. 9. 2020
Published 1. 2. 2021

Regular article

ABSTRACT

The pharmacotherapy treatment of pain is an active and motivated area of investigation for treatment with free side effects. This paper presents the docking ability of twenty-five analogues of 4-Chromanone derivatives inside the crystal structure of \(\mu\) opioid receptor to estimate the binding affinity of each derivative. Molecular modelling design approach applied to identify the effective substation position with generation of 989 novel 4-Chromanone derivatives. The final result of the most active twenty novel 4-Chromanone derivatives with docking affinity range (-9.89 to -9.34) kcal/mol were selected as promising hit ligands drugs comparing with morphine docking affinity at (-6.02) kcal/mol.

INTRODUCTION

Pain (or in particular chronic pain) remains the most significant ongoing global health problem and it is the essential reason why people need medical care leading to decreases the productivity and life quality with socioeconomic problems. Nowadays, there are many available efficient analgesics and painkiller drugs like opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) used in pain treatments, but the main limitation reason of use in therapy is related to their various side effects (Verma et al., 2018). For that, there is a serious need to design and discover new substitutional drugs free of undesirable side effects (Yin et al., 2016). Moreover, the mechanism of pain relief (analgesic or antinociceptive) mainly is involved with the activation of opioid receptor (all four types) by endogenous or exogenous ligands accompanying with many physiological and behavioral effects such as sedation, euphoria, anxiety, respiratory depression, and gastrointestinal transit inhibition (Balcha & Abdela, 2017; Dahan et al., 2018). Chromans (or chromenes) are unique class of bioactive compounds consisting of benzene and pyran fused ring called benzopyrans. The flavones family includes isoflavones, flavonoids, and coumarins have been intensively studied as constituents containing benzopyran ring (Hu et al., 2016). Chromene derivatives possess various pharmacological activities such as antibacterial, antivascular, antimicrobial, anti-inflammatory, antioxidant, TNF-\(\alpha\) inhibitor, antitumor, antiviral, antifungal, anticoagulant, antipsamomlytic, estrogenic, anthelmintic, anti-HIV, herbicidal, analgesic, and anticonvulsant activity (da Silva et al., 2014; Fadda et al., 2012; Hussain et al., 2014; Madenović et al., 2010; Menegutti et al., 2011; Ratnakar Reddy et al., 2014; Sankar et al., 2017). Moreover, 4-Chromanone (or chroman-4-one) is the most common name for the dihydrobenzopyranone. Up to 1971, many of this compounds group were indexed in Chemical Abstracts bulletin as 4-chromanones, but since that year the name has been changed to 2,3-dihydro-4H-1-benzopyran-4-ones (Butler et al., 2010; Wen et al., 2016).

In the field of combinatorial chemistry, scaffold lead hopping is a modern applicable approach refers to the attempt to discover of new medical molecules with higher better or similar bioactivities to the original molecules structures (Zhao, 2007). Many computational methods have been applied to design and generate multi molecules structures by chemical group replacement to achieve new compound similar in skeleton to the active drug to with better activities (Aysla et al., 2014; Brown & Jacoby, 2006). These methods include and subdivide to virtual screening de novo molecular design, topology similarity, pharmacophore search and shape similarity search (Eckert & Bajorath, 2007; Khedkar et al., 2007; Klebe, 2006). In particular, the main aims of chemical group replacement to prevent many biological, chemical, or even intellectual side effects associated to the scaffold of currently used drugs (Abd Razik et al., 2020; Mehdy et al., 2018). In addition, this approach is usually used to enhance ADMET (absorption, distribution, metabolism, excretion, and toxicity) molecule profile and the potency of targeted activity by generating series of molecules as an analogous of the active drug (Lo et al., 2018). In this paper, a series of 4-Chromanone analogues with analgesic activity was collected from literatures and there binding affinity inside \(\mu\) opioid receptor was computationally evaluated (Higgs et al., 2013; Orzubekov et al., 2018). Next, model evaluation and chemical group replacement at selected position was applied to create new 4-Chromanone analogues with higher antinociceptive activity and lower undesirable side effects. The higher active twenty novel 4-Chromanone derivatives were selected as promising hit ligand drugs comparing with best drug for pain treatment (Morphine).

COMPUTATIONAL METHOD

A total of 25 4-Chromanone derivatives structures was obtained from literatures and the 3D derivative conformation was drawn by using ChemDraw16.0 program under ChemOffice package (ChemOffice, 2016). Next step, geometry optimization was perform by MM+ force field using Hyperchem program version 8.0 (Coleman & Arumainayagam, 1998) and saved as .mol file format in sprite files. Furthermore, an additional geometry optimization by semi-empirical approach was applied for RM1 (Reice Model 1) (Rocha et al., 2006). To this step the lowest energy conformation of each molecule is saved as .sdf file format and optimized by using Spartan 14.0 software under windows (Spartan, 2014) with Monte Carlo approach with 100 cycles of optimization, 1000 interactions (Cohen, 1996). Molecular modeling design and molecular docking study were performed by using Glide docking software (Maestro 11.4) under Schrodinger package software (Schrodinger, 2018) for the preparation, minimization and docking studies running on Windows 7 Service Pack 1 operating system on Hp Precision T-1580 workstation (Intel (R) Core (TM) i7 CPU 896 @ 3.5GHz, 16 GB RAM, 1 TB HD). The crystal structures of active \(\mu\) opioid receptor and agonist ligand was obtained from Protein Data Bank under PDB code: 5C1M with crystallographic resolution of 2.1. The receptor preparation steps were applied by ProPrep tool to optimize and protein minimization. This tool used to fill up any missing amino acids, removing of water molecules and ligands with improving of structure resolution. Ligand preparation applied by using LigPrep tool before docking to identify the best orientation and probable ionization position with adding hydrogen atom to achieve lowest energy conformations of each ligand by using OPLS 2005 force field. The size of receptor grid box adjusted to 50 × 50 × 50 Å with a partial atomic charge of 0.27 and during
docking process the receptor kept rigid and ligands were flexible. The best docked orientation and RMSD between protein crystal structure was saved and in order to generate several derivatives with diverse fragment the automated fragment replacement processes was applied. All derivatives were generated and saved by Custom R-Group Enumeration approach under Maestro software by the replacement of hydrogen atom in compound 6.

RESULTS AND DISCUSSION

Over the past decades, opioid receptor has received the most permanent attention as a prominent target for new drug design and discovery due to its essential role in mediating of multi pharmacological issues subjected to behavioral and neurophysiological, including addictive behavior, pain sense, and gastrointestinal motility physiology (Pasternak, 2014). Thus, there has been intensive focus on the design and discovery of novel active ligands toward opioid receptor with high potential efficient therapeutics (Greedy et al., 2013). The successful crystallization process of μ opioid receptor structure in 2015 inspire the ability to estimate the structure activity relationships and binding affinity between ligand and human μ opioid receptor as the target to achieve new painkiller drugs (Huang et al., 2015). In this present work, the theoretical binding affinity application and molecular modeling design combination approaches for the discovery of novel molecules as agonist ligands at active site of human μ opioid receptor. The result of these approaches is a total of twenty-five 4-Chromanone derivatives collected from literatures and docked inside active site of human μ opioid receptor to evaluate the binding affinity of each molecule as shown in table 1.

Table 1 Docking score of substituted 4-Chromanone derivatives collected from literatures

| Compound | Moiety | R₁ | R₂ | R₃ | R₄ | R₅ | R₆ | R₇ | R₈ | Docking Score in kcal/mol |
|----------|--------|----|----|----|----|----|----|----|----|--------------------------|
| 1        | A      | H  | H  | H  | H  | H  | H  | H  | H  | -6.84                    |
| 2        | A      | H  | OH | H  | OH | H  | H  | OH | OCH₃ | -6.95                   |
| 3        | A      | H  | OH | H  | OH | H  | H  | OH | OCH₃ | -6.09                   |
| 4        | B      | H  | H  | H  | H  | H  | H  | H  | H  | -6.38                    |
| 5        | B      | H  | OH | H  | OH | H  | H  | OH | OCH₃ | -7.63                   |
| 6        | B      | OH | OH | H  | OH | H  | H  | OH | OH  | -8.36                   |
| 7        | B      | H  | OH | H  | OH | H  | H  | OH | OCH₃ | -6.96                   |
| 8        | B      | H  | OH | H  | OH | H  | H  | H  | H  | -7.24                    |
| 9        | B      | H  | H  | CH₂ | H  | H  | H  | H  | H  | -6.94                    |
| 10       | B      | H  | H  | NO₂ | H  | H  | H  | H  | H  | -6.22                    |
| 11       | B      | H  | H  | F  | H  | H  | H  | H  | H  | -7.03                    |
| 12       | B      | H  | H  | Cl  | H  | H  | H  | H  | H  | -6.57                    |
| 13       | B      | H  | H  | CH₂ | H  | H  | H  | CH₂ | H  | -5.90                    |
| 14       | B      | H  | H  | CH₂ | H  | H  | H  | Br  | H  | -5.98                    |
| 15       | B      | H  | H  | H  | H  | H  | NO₂ | H  | H  | -4.68                    |
| 16       | B      | H  | H  | H  | H  | H  | NO₂ | H  | H  | -6.12                    |
| 17       | B      | H  | H  | H  | H  | H  | Cl  | H  | H  | -6.89                    |
| 18       | B      | H  | H  | H  | H  | H  | H  | Br  | H  | -7.12                    |
| 19       | B      | H  | H  | H  | H  | H  | H  | CH₂ | H  | -6.50                    |
| 20       | B      | H  | H  | H  | H  | H  | H  | H  | NO₂ | -5.24                    |
| 21       | B      | H  | H  | H  | H  | H  | H  | H  | F  | -5.65                    |
| 22       | B      | H  | H  | H  | H  | H  | H  | H  | Br  | -5.59                    |
| 23       | B      | Br | H  | H  | H  | H  | H  | H  | NO₂ | -6.78                    |
| 24       | B      | Br | Br | H  | H  | H  | H  | Br | H  | -6.63                    |
| 25       | A      | Br | H  | H  | H  | H  | H  | H  | H  | -4.32                    |

In this table, docking score affinity range is between -4.32 kcal/mol for compound 25 to -8.36 kcal/mol for compound 6 with -6.02 kcal/mol for morphine to compare as positive control. These findings refer to the high interesting affinity of compound 6 to bind inside the active site pocket inside opioid receptor comparing with surrounded by the most important amino acids figure 1.

Figure 1 Compound 6 inside μ opioid receptor active site surrounded by amino acids (A) Compound 6 as ball and stick, receptor as ribbon. (B) Ligand interaction view of compound 6
Inside receptor active site, compound 6 bind to TRP318 by tow Pi-Pi stacking interaction bond with both aromatic rings and forming H-bond with hydroxyl group at R₃ position. An additional two H-bond formed between SER53 and SER55 with hydroxyl groups at R₁ and R₂ positions, respectively. Moreover, compound 6 inclosed by the following receptor active site amino acids: SER53, HIS54, SER55, LEU56, TYR75, GLN124, ASN127, TYR128, LYS233, VAL300, LYS303, TRP318, HIS319, and ILE322. Based on docking score result and QSAR model result evaluation, compound 6 was select as lead hit molecule for the next step to apply group replacement at selected effective group position. Figure 2 shows compound 6 (the best active compound) with desirable and undesirable reigns colored in green and yellow contours. These two reigns are labeled and colored depending on the destination of each area as following: Steric bulk undesirable is near yellow, steric bulk desirable is near green, positive charge desirable is near blue, and negative charge desirable is near red.

**Figure 2** Compound 6 (A) with desirable and undesirable contours reigns. (B) Substation position in red shaded cycle.

The green area is referring to the described best reign to replace with promising potency. From this point, hydroxyl group at R₁ position was select to be replaced by many deferent chemical groups from database. After performing molecular group replacement generation, a total of 989 new 4-Chromanone derivatives were docked, recorded, and the higher best twenty molecules are listed dissenting in table 2. Among all derivatives, a total of sixty-eight compound were better than morphine. The substituted group replacement by alpha-methylstyrene group at position R₃ result a high active compound N01 with high docking score -9.89 kcal/mol. This increasing in binding affinity accompanied with very good orientation inside the receptor active site and inclosed by important amino acids figure 3.

**Table 2** Docking score of the best generated twenty derivatives of compound 6

| Compound | R | Docking Score in kcal/mol | Compound | R | Docking Score in kcal/mol |
|----------|---|--------------------------|----------|---|--------------------------|
| N01 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(4-prop-1-en-2-yl)phenoxy)-4H-chromen-4-one | | -9.89 | N02 3-(4-(2-chloroethyl)phenoxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one | | -9.88 |
| N03 2-(3,4-dihydroxyphenyl)-3-(3-ethyl-5-methylphenoxy)-5,7-dihydroxy-4H-chromen-4-one | | -9.86 | N04 3-(3,5-dichloro-4-hydroxyphenoxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one | | -9.85 |
| N05 (E)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-(methylamino)methylyphenoxy)-4H-chromen-4-one | | -9.75 | N06 2-(3-(2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yloxy)phenyl)acetonitrile | | -9.50 |
| N07 2-(3-(2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yloxy)phenyl)acetonitrile | | -9.44 |
Inside active site compound N01 bind by three Pi-Pi stacking interactions HISS4 from three aromatic rings. Another two interactions with hydroxyl group by H-bond interactions with LYS233 and HISS4. Moreover, all the active important amino acids inclosed with this compound supported with the previous interactions. The existing of these interactions helps to increase the binding affinity and activity of any compound inclosed inside active site. In contrast, between many interesting and well-known μ opioid receptor active ligands, these twenty compounds consider as new novel chemical scaffolds. It is referring to that hits selection group replacement molecule approaches usually will provide better active compound than the compounds in virtual screening models.

**CONCLUSION**

In drug design, scaffold hopping is one of the best important approach in molecular discovery and design to improve potency or binding affinity selection. In this present paper, the result of applying this concept was a novel 4-Chromanone analogues with higher pharmacological profile and binding affinity inside active site of human μ opioid receptor. This is materialized by high binding affinity among a total of sixty-eight compounds better than morphine within a range of (-9.89 to -9.34) kcal/mol for the highest twenty compounds promoted with Pi-Pi stacking and H-bond interactions. Further biological and pharmacological evaluation is required to understand the side effects of all novel portentous drugs.

**REFERENCES**

Abd Razik, B. M., Ezmat, M. O., & Al-Shohani, A. D. H. (2020). Molecular Docking and Design Study for Anticancer Activity of Flavonoid Derivatives Against Breast Cancer. Indian Drugs, 57(4), 7–14. https://doi.org/10.11591/ijaas.v3.i3.pp151

Aysha, O. S., Mohammed, M. P., & Dhamotharan, R. (2014). Insilico Identification of Potent Inhibitor from Andrographis Paniculata for ESBLs. *International Journal of Advances in Applied Sciences*, 3(3), 151–157. https://doi.org/10.11591/ijaas.v3.i3.pp151-157

Balcha, C., & Abdela, N. (2017). Review of Rabies Preventions and Control. *International Journal of Public Health Science (IJPBS)*, 6(4), 343. https://doi.org/10.11591/JPBHS.V6I4.10781

Brown, N., & Jacoby, E. (2006). On scaffolds and hopping in medicinal chemistry. *Mini Reviews in Medicinal Chemistry*, 6(11), 1217–1229. https://doi.org/10.2174/138955706787542768

Butler, J. D., Conrad, W. E., Lodewyk, M. W., Fettinger, J. C., Tantillo, D. J., & Kurth, M. J. (2010). Synthesis of Substituted Chromanones: An Organoanionic Aldol/Oxa-Michael Reaction. *Organic Letters*, 12(15), 3410–3413. https://doi.org/10.1021/ol101221c

Cohen, N. (1996). *Guidebook on Molecular Modeling in Drug Design*. https://doi.org/10.1016/0075-3322(97)86919-3

Coleman, W. F., & Arumainayagam, C. R. (1998). HyperChem 5 (by Hypercube, Inc.). *Journal of Chemical Education*, 75(4), 416. https://doi.org/10.1021/ed075p416

| **Table** | **Compounds** | **Molecular Structures** | **Binding Affinity** |
|----------|--------------|--------------------------|---------------------|
| N06      | 3-(1H-inden-6-yl)oxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one | ![Molecular Structure](image1.png) | 9.75 |
| N07      | 3-((2,3-dihydro-1H-inden-5-yl)oxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one | ![Molecular Structure](image2.png) | 9.74 |
| N08      | 3-(4-chloro-3-(methylthio)phenoxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one | ![Molecular Structure](image3.png) | 9.73 |
| N09      | (E)-2-(3,4-Dihydroxyphenyl)-3-(4-ethylideneamino)phenoxy)-5,7-dihydroxy-4H-chromen-4-one | ![Molecular Structure](image4.png) | 9.69 |
| N10      | (E)-2-(3,4-dihydroxyphenyl)-3-(4-ethylideneamino)phenoxy)-5,7-dihydroxy-4H-chromen-4-one | ![Molecular Structure](image5.png) | 9.65 |
| N16      | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(4-methyl-3-(methylthio)phenoxy)-4H-chromen-4-one | ![Molecular Structure](image6.png) | 9.41 |
| N17      | 3-(3-(difluoromethyl)phenoxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one | ![Molecular Structure](image7.png) | 9.38 |
| N18      | 3-(3-chloro-4-(methylamino)phenoxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one | ![Molecular Structure](image8.png) | 9.37 |
| N19      | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(1,2,4,5-tetramethyl-1H-pyrrol-3-yl)oxy)-4H-chromen-4-one | ![Molecular Structure](image9.png) | 9.35 |
| N20      | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(5-methyl-1-propyl-1H-pyrrol-3-yl)oxy)-4H-chromen-4-one | ![Molecular Structure](image10.png) | 9.34 |

**Figure 3** Compound N01 inclosed by most important amino acids inside human μ opioid receptor active site (A) Compound N01 as ball and stick, receptor as ribbon. (B) Ligand interaction view of compound N01.
Antimicrobial Activity of Azetidinone and Thiazolidinone Derivatives from Azolylindolyl Schiff’s Bases. *Chemistry, 7(11),* 340–347. https://doi.org/10.2174/187444800782310543

Verma, U. P., Ahlaba, G., & Disha, S. (2018). Role of Curcuma longa in the Management of Gingivitis. *International Journal of Public Health Science (IPHS),* 7(3), 216. https://doi.org/10.11591/ijphs.v7i3.14830

Wen, G., Su, Y., Zhang, G., Lin, Q., Zhu, Y., Zhang, Q., & Fang, X. (2016). Stereoevgergent Synthesis of Chromanones and Flavanones via Intramolecular Benzoin Reaction. *Organic Letters,* 18(16), 3980–3983. https://doi.org/10.1021/acs.orglett.6b01767

Yin, Z. Y., Li, L., Chu, S. S., Sun, Q., Ma, Z. L., & Gu, X. P. (2016). Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. *Scientific Reports,* 6, 27129. https://doi.org/10.1038/srep27129

Zhao, H. (2007). Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. *Drug Discovery Today,* 12(3–4), 149–155. https://doi.org/10.1016/j.drudis.2006.12.003

---

d'a Silva, I. M., da Silva Filho, J., Santiago, P. B. G. da S., do Egito, M. S., de Souza, C. A., Gouveia, F. L., Ximenes, R. M., de Sena, K. X. da F., de Faria, A. R., Brondani, D. J., & de Albuquerque, J. F. C. (2014). Synthesis and Antimicrobial Activities of 5-Arylidene-thiazolidine-2,4-dione Derivatives. *BioMed Research International,* 2014, 1–8. https://doi.org/10.1155/2014/3169082

Dahan, A., van der Schrier, R., Smith, T., Aarts, L., van Velzen, M., & Niesters, M. (2018). Averting Opioid-induced Respiratory Depression without Affecting Analgesia. *Anesthesiology,* 128(5), 1027–1037. https://doi.org/10.1097/ALN.0000000000002184

Eckert, H., & Bajorath, J. (2007). Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. *Drug Discovery Today,* 12(5–6), 225–233. https://doi.org/10.1016/j.drudis.2007.01.011

Fadda, A. A., Berghot, M. A., Amer, F. A., Badawy, D. S., & Bayoumy, N. M. (2012). Synthesis and Antioxidant and Antitumor Activity of Novel Pyridine, Chromone, Thiochromene and Thiazole Derivatives. *Archi Der Pharmacie,* 34(5), 378–385. https://doi.org/10.1002/ardp.201100335

Greedy, B. M., Bradbury, F., Thomas, M. P., Grivas, K., Cami-Kobicci, G., Archambeau, A., Bosse, K., Clark, M. J., Aceto, M., Lewis, J. W., Traynor, J. R., & Husband, S. M. (2013). Orvins with mixed kappa/mu opioid receptor agonist activity. *Journal of Medicinal Chemistry,* 56(8), 3207–3216. https://doi.org/10.1021/jm301543z

Higgs, J., Wasowski, C., Loscalzo, L. M., & Marder, M. (2013). In vitro binding affinities of a series of flavonoids for μ-opioid receptors. Antinociceptive effect of the synthetic flavonoid 3,3-dibromoflavonane in mice. *Neuropharmacology,* 72, 9–19. https://doi.org/10.1016/j.neuropharm.2013.04.020

Hu, N. J., Wang, Z., & Tang, W. (2016). Synthesis of Chiral 1, 4-Benzoxidoxanes and Chromans by Enantioselective Palladium-Catalyzed Alkene Arlyloxycyclarations. *Angewandte Chemie International Edition,* 55(16), 5044–5048. https://doi.org/10.1002/anie.201600037

Huang, W., Manglik, A., Venkatakrishnan, A. J., Laeremans, T., Feinberg, E. N., Sambha, A. I., Kato, H. E., Livingston, K. E., Thoren, K. S., Kung, R. C., Granier, S., Gmeiner, P., Husbands, S. M., Traynor, J. R., Weis, W. L., Steyaert, J., Dorr, R. O., & Kobilka, B. K. (2015). Structural insights into μ-opioid receptor activation. *Nature,* 524(7565), 315–321.

Hussain, M. K., Ansari, M. I., Yadav, N., Gupta, P. K., Gupta, A. K., Saxena, R., Fatima, I., Manohar, M., Kushwaha, P., Khedgikar, V., Gautam, J., Kant, R., Maulik, P. R., Trivedi, R., Dwivedi, A., Kumar, K. R., Saxena, A. K., & Hajela, K. (2014). Design and synthesis of ERα/ERβ selective coumarin and chromene derivatives as potential anti-breast cancer and anti-osteoporotic agents. *RSC Adv.,* 4(17), 8828–8835. https://doi.org/10.1039/C4RA03794D

Khedr, S. A., Malde, A. K., Coutinho, E. C., & Srivastava, S. (2007). Pharmacophore modeling in drug discovery and development: an overview. *Medicinal Chemistry (Sharjah (United Arab Emirates)),* 3(2), 187–197. https://doi.org/10.2174/157340607780059521

Klebe, G. (2006). Virtual ligand screening: strategies, perspectives and limitations. *Drug Discovery Today,* 11(13–14), 580–594. https://doi.org/10.1016/j.drudis.2006.05.012

Lo, Y.-C., Rensi, S. E., Torng, W., & Altman, R. B. (2018). Machine learning in chemoinformatics and drug discovery. *Drug Discovery Today,* 23(8), 1538–1546. https://doi.org/10.1016/j.drudis.2018.05.010

Mehdy, M. A., Graziano, M., & Piccinini, G. (2018). Simulation and modeling of silicon based single electron transistor. *International Journal of Electrical and Computer Engineering,* 8(2), 900–907. https://doi.org/10.1515/ieece.v8i2.p900-907

Mladenovic, M., Vukovic, N., Sukdolak, S., & Solujic, S. (2010). Design of Novel 4-Hydroxy-chromene-2-one Derivatives as Antimicrobial Agents. *Molecules,* 15(6), 4294–4308. https://doi.org/10.3390/molecules15064294

Mungra, D. C., Patel, M. P., Rajani, D. P., & Patel, R. G. (2011). Synthesis and Identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene Derivatives as a New Class of Antimicrobial and Antituberculosis Agents. *European Journal of Medicinal Chemistry,* 46(9), 4192–4200. https://doi.org/10.1016/j.ejmech.2011.06.022

Orazbekov, Y., Ibrahim, M. A., Mombekov, S., Srivedavasrasri, R., Dakhayev, U., Makhatov, B., Chaurasia, N. D., Tekwani, B. L., & Ross, S. A. (2018). Isolation and Biological Evaluation of Prenylated Flavanoids from Machura pomifera. *Evoked Atropinized Cholinergic and Alternative Medicine,* 2018, 1–8. https://doi.org/10.1155/2018/1370568

Pasternak, G. W. (2014). Opiate pharmacology and relief of pain. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology,* 32(16), 1655–1661. https://doi.org/10.1200/JCO.2013.53.1079

Ratnakarreddy, K., Sambasiv Rao, P., Jitender Dev, G., Poornachandara, Y., Ganasewaru, C., Shanthan Rao, P., & Narsaiah, B. (2014). Synthesis of novel 1,2,3-triazole/soxazole functionalized 2H-Chromene derivatives and their cytotoxic activity. *Bioorganic & Medicinal Chemistry Letters,* 24(7), 1661–1663. https://doi.org/10.1016/j.bmcl.2014.03.009

Rocha, G. B., Freire, R. O., Simas, A. M., & Stewart, J. J. P. (2006). RM1: A Reparameterization of AM1 for H, C, N, O, P, S, F, Cl, Br, and I. *Journal of Computational Chemistry,* 27(10), 1101–1111. https://doi.org/10.1002/jcc.20425

Sankar, P. S., Divya, K., Padmana, A., & Padmavathi, V. (2017). Synthesis and